Shanghai Medicilon Inc. (SHA:688202)

Shanghai Medicilon Revenue

Shanghai Medicilon had revenue of 396.83M CNY in the quarter ending June 30, 2026, with 45.19% growth. This brings the company's total for the last twelve months to 1.38B, up 30.98% year-over-year. In the year 2025, Shanghai Medicilon had annual revenue of 1.16B with 12.08% growth. That makes Shanghai Medicilon the 17,217th largest company in the world by revenue and 3,115th in China.

• Revenue (ttm): 1.38B
• Revenue Growth: +30.98%
• P/S Ratio: 7.40
• Revenue / Employee: 497.89K
• Employees: 2,780
• Market Cap: 10.25B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Preclinical Study 589.91M 50.7%
• Drug Discovery and Pharmaceutical Research 573.03M 49.3%

By Geography

Chart

• China 614.58M 52.8%
• Overseas 548.36M 47.2%

Fiscal year ended Dec 31, 2025 See the full Shanghai Medicilon breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.16B	125.32M	12.08%
Dec 31, 2024	1.04B	-327.89M	-24.01%
Dec 31, 2023	1.37B	-293.30M	-17.68%
Dec 31, 2022	1.66B	491.67M	42.12%
Dec 31, 2021	1.17B	501.31M	75.28%

Data Source: S&P Global Market Intelligence Last updated: Aug 24, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 20, 2026

Data Sources Report a data error